Por favor, use este identificador para citar o enlazar este ítem:
http://sgc.anlis.gob.ar/handle/123456789/2715| Título : | GII.17 norovirus re-emerged in the 2020s as a result of dynamic and adaptive evolutionary processes | Autor : | Tohma, Kentaro Jacobsen, Sonja Altmann, Britta Kendra, Joseph A, Landivar, Michael De LaO, William E. Fernandez Garcia, Maria Dolores Gomes, Karina Chudnovsky, Sophia Ford Siltz, Lauren A. Pilewski, Kelsey A. Gao, Yamei Mazo, Ilya Niendorf, Sandra Parra, Gabriel Ignacio |
Palabras clave : | Genotipo;Mutación;variacion genetica;Filogenia;ARN Viral;Virus;Brotes de Enfermedades;Fenotipo | Fecha de publicación : | 24-nov-2025 | Resumen : | Over the past two years, increased norovirus activity has been reported in multiple countries, accompanied by a rise in genotype GII.17 prevalence. Despite causing large outbreaks in Asia during 2014-2016, GII.17 has not historically been considered a predominant genotype. In this study, using 1471 archival and newly-identified GII.17 genomes, we investigated (i) global diversification patterns of this virus at the whole-genome level, (ii) in-depth mutational patterns within 511 viruses detected during a 10-year national survey in Germany, and (iii) intra-host viral diversity and adaptation processes that lead to the predominance of the GII.17 virus. The recent GII.17 norovirus exhibited extensive genetic diversity and multiple back-and-forth and recurrent mutations during the early phase of its epidemic; however, this diversity declined by 2024, suggesting that the virus had reached a phenotype efficient for human infection. Experimental data confirmed that mutations in the viral capsid enhanced binding to host factors associated with virus entry and resulted in antigenic changes compared to previously circulating clusters. Overall, this study demonstrated that the recent surge of GII.17 resulted from a dynamic, multifaceted process involving diverse adaptive strategies, ultimately enabling the virus to achieve sustained transmission within the human population. |
Descripción : | English, 17 pages. Fil: Tohma, Kentaro. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration; Silver Spring, MD, USA. Fil: Jacobsen, Sonja. Department of InfectiousDiseases, Robert Koch Institute; Berlin, Germany. Fil: Altmann, Britta. Department of Infectious Diseases, Robert Koch Institute; Berlin, Germany. Fil: Kendra, Joseph A. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration; Silver Spring, MD, USA. Fil: Landivar, Michael. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration; Silver Spring, MD, USA. Fil: De LaO, William E. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration; Silver Spring, MD, USA. Fil: Fernandez Garcia, Maria Dolores. Enterovirus and Viral Gastroenteritis Unit, National Centre for Microbiology, Instituto de Salud Carlos III; Madrid, Spain. CIBER Epidemiology and Public Health (CIBERESP); Madrid, Spain. FIl: Gomes, Karina. Laboratory of Viral Gastroenteritis, INEI-ANLIS “Dr.CarlosG.Malbrán”; Buenos Aires, Argentina. FIl: Chudnovsky, Sophia. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration; Silver Spring, MD, USA. FIl: Ford Siltz, Lauren A. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration; Silver Spring, MD, USA. Fil: Pilewski, Kelsey A. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration; Silver Spring, MD, USA. Fil: Gao, Yamei. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration; Silver Spring, MD, USA. Fil: Mazo, Ilya. FDA HIVE, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Fil: Niendorf, Sandra. Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany Fil: Parra, Gabriel Ignacio. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration; Silver Spring, MD, USA. |
URI : | http://sgc.anlis.gob.ar/handle/123456789/2715 | DOI: | 10.1038/s41467-025-66279-6 |
| Aparece en las colecciones: | Publicaciones INEI |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| 41467_2025_Article_66279.pdf | English, 17 pages | 13.5 MB | Adobe PDF | Visualizar/Abrir |
Visualizaciones de página(s)
86
comprobado en 27-ago-2026
Descarga(s)
14
comprobado en 27-ago-2026
Google ScholarTM
Consultar
Altmetric
Altmetric
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.

